ReNeuron Group (RENE.L) Stock Price
ReNeuron Group Price
Revenue has compounded at 26.3% per year over the past 17 years to 530,000.00 GBP. ReNeuron Group's net margin stands at -1,020.8%, up from -28,700.0% several years earlier.
ReNeuron Group stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of ReNeuron Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ReNeuron Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ReNeuron Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | ReNeuron Group Price |
|---|
ReNeuron Group Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
ReNeuron Group Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM GBP |
|---|
| REVENUE GROWTH% |
| EBITM GBP |
| EBIT MARGIN% |
| NET INCOMEM GBP |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | 6.00 | – | – | – | – | 12.00 | 1.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -91.67 |
| -6.00 | -6.00 | -7.00 | -7.00 | -10.00 | -13.00 | -18.00 | -20.00 | -18.00 | -14.00 | -12.00 | -11.00 | -7.00 | -6.00 | 4.00 | -11.00 |
| – | – | – | – | – | – | – | – | – | -233.33 | – | – | – | – | 33.33 | -1,100.00 |
| -6.00 | -6.00 | -6.00 | -7.00 | -8.00 | -11.00 | -15.00 | -17.00 | -14.00 | -11.00 | -11.00 | -9.00 | -5.00 | – | – | -11.00 |
| 20.00 | – | – | 16.67 | 14.29 | 37.50 | 36.36 | 13.33 | -17.65 | -21.43 | – | -18.18 | -44.44 | – | – | – |
| 5.03 | 6.41 | 7.69 | 14.63 | 18.37 | 26.80 | 32.50 | 32.50 | 32.50 | 32.67 | 39.13 | 56.98 | 57.13 | 57.13 | 57.13 | 57.13 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales ReNeuron Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ReNeuron Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ReNeuron Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares ReNeuron Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ReNeuron Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
ReNeuron Group stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
ReNeuron Group Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
ReNeuron Group business model & stock analysis
ReNeuron Group SWOT Analysis
Strengths
1. Advanced stem cell therapy technology: ReNeuron Group PLC possesses cutting-edge stem cell therapy technology, which gives them a competitive advantage over other companies in the field.
2. Strong intellectual property (IP) portfolio: The company has a robust IP portfolio that provides them with legal protection and allows them to commercialize their therapies without significant competition.
3. Successful clinical trials: ReNeuron has a track record of successful clinical trials, demonstrating the effectiveness and safety of their therapies. This strengthens their credibility and increases investor confidence.
Weaknesses
1. Limited product portfolio: ReNeuron currently focuses on a narrow range of therapies, limiting their revenue streams and making them vulnerable to market fluctuations.
2. High research and development costs: The development and refinement of stem cell therapies require significant investments, which can put strain on ReNeuron's financial resources.
3. Regulatory uncertainties: The regulatory landscape surrounding stem cell therapies is evolving, and changes in regulations or approval processes may impact ReNeuron's ability to bring their products to market.
Opportunities
1. Growing market demand: The demand for regenerative medicine and innovative therapies is increasing globally, providing ReNeuron with opportunities to expand their customer base and generate more revenue.
2. Collaborations and partnerships: ReNeuron can explore strategic partnerships with pharmaceutical companies, research institutions, and healthcare organizations to accelerate product development, access new markets, and share resources.
3. Emerging markets: ReNeuron can target emerging markets where the adoption of stem cell therapies is still at a nascent stage, allowing for early market entry and potentially higher returns.
Threats
1. Intense competition: The field of stem cell therapy is highly competitive, with several established companies and new entrants vying for market share. ReNeuron faces the risk of losing customers to competitors.
2. Regulatory hurdles: Changes in regulations, particularly related to safety and efficacy requirements for stem cell therapies, could delay or prevent ReNeuron from obtaining necessary approvals or licenses.
3. Economic constraints: Economic downturns or budget cuts in healthcare spending can impact the financial stability of potential customers and limit their willingness to invest in advanced therapies, affecting ReNeuron's revenue.
ReNeuron Group Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
ReNeuron Group historical P/E ratio, EBIT multiple, and P/S ratio
ReNeuron Group annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
ReNeuron Group shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
ReNeuron Group stock splits
ReNeuron Group Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 7/6/2022 | -0.11GBP | - | 0.00GBP | - | 2022 Q4 |
| 7/8/2021 | -0.13GBP | - | 1.01 MGBP | - | 2021 Q4 |
| 7/20/2020 | -0.21GBP | - | 3.04 MGBP | - | 2020 Q4 |
| 12/6/2019 | -0.16GBP | - | 5.87 MGBP | - | 2020 Q2 |
| 7/11/2019 | -0.37GBP | - | 507,499.00GBP | - | 2019 Q4 |
ReNeuron Group shareholder structure
| % | Name |
|---|---|
2.10386% | |
0.61264% | |
0.21998% | |
0.19298% | |
0.13526% | |
0.06236% |
ReNeuron Group Executives and Management Board
8 members · avg. age 57 · 25 % women
Mr. John Hawkins (57)
Chief Financial Officer, Director · since 2021
98,000.00 GBP
Management
Ms. Suzanne Hancock
Chief Operations Officer
Dr. Randolph Corteling
Chief Scientific Officer
Mr. Simon Dew
Chief Business Officer
Board of Directors
Mr. Iain Ross
Executive Chairman of the Board · since 2021
Ms. Barbara Staehelin (60)
Senior Independent Non-Executive Director
Mr. Martin Walton (60)
Non-Executive Independent Director
Dr. Michael Owen (51)
Non-Executive Independent Director
ReNeuron Group Supply Chain
ReNeuron Group Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.53 | 0.79 | 0.41 | ||
| 2 | Shanghai Fosun Pharm H | 0.36 | 0.67 | 0.31 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.83 | 0.27 | -0.34 |
Frequently asked questions about ReNeuron Group
The business model of ReNeuron Group PLC is focused on developing and commercializing cell-based therapies for the treatment of diseases and injuries. The company specializes in stem cell research and uses its unique proprietary technologies to create advanced therapies for conditions like stroke, retinal diseases, and peripheral arterial disease. ReNeuron Group PLC aims to capitalize on the potential of cell-based treatments and is dedicated to advancing the field of regenerative medicine. By leveraging their expertise in stem cell science, the company strives to provide innovative solutions that address significant unmet medical needs and improve patient outcomes.
ReNeuron Group PLC is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of ReNeuron Group PLC in the market include companies such as StemCells Inc., Athersys Inc., and Mesoblast Limited.
ReNeuron Group PLC is a leading biotechnology company specializing in the development of cell-based therapies. Founded in 1997, ReNeuron has built a solid reputation for its groundbreaking research in stem cell technologies. The company focuses on developing treatments for various debilitating diseases, including stroke, retinitis pigmentosa, and critical limb ischemia. With its innovative therapies and committed research efforts, ReNeuron aims to provide effective, long-term solutions for patients in need. Over the years, ReNeuron Group PLC has garnered recognition for its scientific advancements and remains dedicated to advancing the field of regenerative medicine.
ReNeuron Group PLC, a leading biotech company, has achieved several significant milestones. They have successfully developed and launched their innovative stem cell therapies, revolutionizing the field of regenerative medicine. The company has also conducted successful clinical trials, demonstrating the safety and efficacy of their treatments. ReNeuron has formed strategic partnerships with renowned academic institutions and pharmaceutical companies, further boosting their research and development capabilities. Additionally, they have received regulatory approvals for their therapies, paving the way for commercialization. ReNeuron Group PLC continues to make remarkable strides in unlocking the potential of stem cells for treating a range of debilitating diseases.
ReNeuron Group PLC is primarily present in the United Kingdom.
ReNeuron Group PLC represents strong values and a corporate philosophy centered on innovation and excellence in the field of regenerative medicine. With an unwavering commitment to improving patients' lives, ReNeuron focuses on developing novel cell-based therapies to address critical medical needs. Their scientific expertise and state-of-the-art research facilities enable the company to advance groundbreaking treatments for conditions such as stroke and retinal diseases. ReNeuron Group PLC strives for ongoing collaboration with leading healthcare professionals and industry partners to deliver transformative therapies that have the potential to revolutionize the healthcare landscape.
5 analysts currently rate the ReNeuron Group stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect ReNeuron Group to generate revenue of 1.19 M GBP and earnings per share of -0.20 GBP.
The ReNeuron Group share (RENE.L) is listed on 4 stock exchanges, including: Frankfurt (RQE.F), London (RENE.L), London (RENE.L).
The ReNeuron Group PLC is a biopharmaceutical company that focuses on the development of cell therapies for serious diseases. The business model of ReNeuron Group includes three different divisions: therapeutics, research, and services.
The expected revenue of ReNeuron Group is 1.19 M GBP. This figure is based on current financial data and reflects the company's business performance.
The expected profit of ReNeuron Group is -11.23 M GBP. The net profit reflects the company's profitability after deducting all expenses.
The P/E ratio cannot be calculated for ReNeuron Group at the moment.
The P/S cannot be calculated for ReNeuron Group currently.
The Eulerpool Quality Score for ReNeuron Group is 3/10.
The ISIN of ReNeuron Group is GB00BF5G6K95. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of ReNeuron Group is A2JBKZ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of ReNeuron Group is RENE.L. The ticker symbol is used to trade ReNeuron Group shares on the stock exchange.
ReNeuron Group is assigned to the 'Health' sector.
The dividends of ReNeuron Group are distributed in GBP.
ReNeuron Group stock
ReNeuron Group Peer Group
ReNeuron Group Ticker
ReNeuron Group FIGI
All fundamentals and in-depth analysis of ReNeuron Group
Our stock analysis for ReNeuron Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ReNeuron Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.